Fierce Pharma Asia—Enhertu's neoadjuvant win; Takeda eyes inflection point; Trump targets foreign plants
Enhertu delivered a trial win in early-stage breast cancer. Takeda spotlighted three late-stage readouts as a potential "inflection point" for the company. President Donald Trump is directing the FDA to go hard on foreign manufacturing facilities. And more.
Enhertu delivered a trial win in early-stage breast cancer. Takeda spotlighted three late-stage readouts as a potential "inflection point" for the company. President Donald Trump is directing the FDA to go hard on foreign manufacturing facilities. And more.
